

FDA Proposes New Conflict-of-Interest Limits

BY ALICIA AULT

Associate Editor, Practice Trends

The Food and Drug Administration is proposing to beef up its conflict-of-interest guidelines for experts who serve on its advisory committees, the agency announced in a teleconference.

Proposed guidelines would bar experts with stock or other financial interests worth more than \$50,000 in a particular company from reviewing that manufacturer's product, and ban voting by those who receive or own less than \$50,000.

The \$50,000 rule would be applied to any holdings or interest within 12 months of an advisory panel meeting.

The proposal was billed by FDA officials as an upgrade of guidelines that have been in effect since 2000 and were made partly

In the past, even nonvoting members could influence a panel's decision. The new proposal for stricter guidelines will act as a countermeasure.

in response to public demands for more accountability, according to Randall Lutter, FDA acting deputy commissioner for policy.

The FDA "is committed to making the advisory committee process more rigorous

and transparent so that the public has confidence in the integrity of the recommendations made by its advisory committees," Mr. Lutter said in a statement issued by the agency.

However, in the briefing, he said the FDA "was not aware of any instances where decision making has been adversely affected by conflicts members might have." The new guidance attempts to balance the quest for transparency with the need for qualified experts, Mr. Lutter said.

As in the past, the guidelines are not legally binding. They are offered as suggestions to staff evaluating potential conflicts of interest by both government and nongovernment employees.

It is rare for staff to make decisions that fall outside of the guidance, though, and waivers will likely only rarely be granted, Mr. Lutter said.

For instance, if a panel member has received an individual grant or other fee of less than \$50,000 from a company for work in the hematology area, but is reviewing the company's cardiology drug or device, that person might be allowed to participate in the panel meeting.

Mr. Lutter and other agency officials would not say how they came up with the \$50,000 threshold or how many current advisory panel members might be disqualified based on that figure.

However, Mr. Lutter said, "our judgment is, it is a significant number."

The restriction applies to stocks and investments, primary employment, consulting work, contracts and grants, royalties, expert witness work, and speaking and writing fees. It does not apply to mutual funds. The \$50,000 figure will be increased

each year in line with the consumer price index, according to the proposal.

A critic of the FDA's conflict-of-interest policies said the new guidance is a significant step forward in part because it will bar participants from voting if they have a financial conflict. They "will be identified as committee members with a taint," said Peter Lurie, deputy director of Public Citizen's Health Research Group.

In the past, even nonvoting members could influence a panel's decision, he said,


adding that the new proposal will act as a "countermeasure."

The proposed rules also could "drive the conflict rate lower," Mr. Lurie said, noting that when it comes to recruiting new advisory committee members, "there's going to be a premium on finding those who don't have conflicts."

The guidance document was posted on the FDA's Web site on March 21. Once it is published in the Federal Register, it will be open for public comment for 60 days.

The agency expects to incorporate suggestions and issue the final guidance shortly after that time, Mr. Lutter said. ■

To submit electronic comments, visit www.regulations.gov or www.fda.gov/dockets/ecomments. Written comments may be sent to: Division of Dockets Management (HFA-305), U.S. Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD, 20852. Comments must include the docket number 2007D-0101.



Discover **Levemir**[®]:
a long-acting basal insulin
with a light touch

Levemir: for your patients who need a safe and effective way to improve A1C control

With proven reductions in A1C and FPG levels over time, Levemir can help your patients get to goal with up to 24 hours of glycemic control. Patients with diabetes can experience a consistent blood glucose response from injection to injection. Less weight gain was observed with Levemir in 12 of 12 clinical trials.* And Levemir is available in the Levemir[®] FlexPen[®]. FlexPen[®] is the world's #1 selling prefilled insulin pen.* So start your patients with diabetes on Levemir, and help them experience the light side of basal insulin.

Levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information
Levemir should not be diluted or mixed with any other insulin preparations.

Levemir is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin dose should be made cautiously

and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Levemir is not to be used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or long-acting insulin preparations. The dose of Levemir may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients

in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir and NPH insulin is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.



Levemir[®]
insulin detemir (rDNA origin) injection
Lighter years ahead



Reference: 1. IMS Health, IMS MIDAS [12 months ending September 2005].

Please see brief summary of Prescribing Information on adjacent page. FlexPen and Levemir are registered trademarks of Novo Nordisk A/S.

© 2006 Novo Nordisk Inc. 131007 September 2006